GlassScriptPhysician profile
Allison Cowan
NPI 1649863184
$2,186.90
in general payments reported to CMS, 2019-2025
33 companies · $22.05 in 2025
The $22.05 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $858 · 2022: $1,094 · 2023: $213 · 2025: $22.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $234.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $291.83 | 2021-2022 | |
| Abbvie INC. | $218.93 | 2021-2025 | |
| Inari Medical, INC. | $212.74 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Glaxosmithkline, LLC. | $174.46 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.28 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $118.74 | 2021-2022 | |
| Lilly USA, LLC | $101.08 | 2021-2022 | |
| Nuvasive, INC. | $84.02 | 2022 | |
| Amgen INC. | $80.90 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $75.14 | 2021-2022 | |
| Mylan Specialty L.P. | $66.44 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.24 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.76 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $47.37 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $42.51 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.66 | 2022 | |
| Eisai INC. | $37.99 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $37.36 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $33.77 | 2021 | |
| Astellas Pharma US INC | $32.12 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.97 | 2022 | |
| Pfizer INC. | $21.88 | 2021 | |
| Abbott Laboratories | $20.19 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.75 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.68 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.38 | 2021 | |
| Axsome Therapeutics, INC. | $15.51 | 2022 | |
| Antares Pharma, INC. | $15.08 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.78 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.69 | 2022 | |
| Collegium Pharmaceutical, INC. | $13.64 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.21 | 2022 | |
| Lundbeck LLC | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Cowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.